COVID-19 is Disrupting Some Alzheimer’s Clinical Trials
By Phil Gutis | March 25th, 2020
The response was disappointing but not particularly surprising. Earlier in the day, I had sent a quick email to check in with the staff…
First Patient Receives Biogen’s Alzheimer’s Drug, Aducanumab, in New Trial
By Phil Gutis | March 13th, 2020
Being Patient Senior Reporter Phil Gutis spent the day with our patient advisor, Jeff Borghoff, who was the first recipient in Biogen’s latest trial…
When Alzheimer’s Trials Are Cancelled: Notifying Study Participants in the Most ‘Humane’ Way
By Phil Gutis | February 28th, 2020
Almost a year ago, the phones and social media feeds of about 4,000 people around the world began to explode. Biogen had unexpectedly—and quite…
FDA Gives Biogen Green Light to Relaunch Aducanumab Study on Trial Participants
By Phil Gutis | January 28th, 2020
The U.S. Food and Drug Administration (FDA) has approved a re-dosing study for patients formerly enrolled in Biogen’s phase three clinical trials of its…
Clinical Trial Participant Reacts to News Biogen’s Alzheimer’s Drug May Have Been Working
By
Being Patient
| December 13th, 2019
Clinical Trial Participant Reacts to News Biogen's Alzheimer's Drug Aducanumab May Have Been WorkingWatch this video on YouTube Biogen has announced new data behind…
Biogen Trial Participant Seeks to Understand Science Behind Alzheimer’s Drug
By Phil Gutis | December 6th, 2019
SAN DIEGO — I’m not a doctor. I’m not a scientist. I barely made it through my math and science classes in college. Actually,…
Biogen Dropped Me From Their Cancelled Alzheimer’s Study; Now They’re Bringing It Back
By Phil Gutis | October 22nd, 2019
I wasn’t yet fully awake this morning when I started poking through my Facebook feed and saw the head-spinning news that Biogen had reversed…
Follow us